A5066392289- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Protease and Inhibitor Mechanisms
- Glycosylation and Glycoproteins Research
- Angiogenesis and VEGF in Cancer
- Blood Coagulation and Thrombosis Mechanisms
- Blood properties and coagulation
- Radiopharmaceutical Chemistry and Applications
- Cancer, Hypoxia, and Metabolism
- Immune Cell Function and Interaction
- Cell Adhesion Molecules Research
- T-cell and B-cell Immunology
- Cancer Immunotherapy and Biomarkers
- SARS-CoV-2 and COVID-19 Research
- Hemophilia Treatment and Research
- RNA Interference and Gene Delivery
- Nanofabrication and Lithography Techniques
- Biosimilars and Bioanalytical Methods
- Peptidase Inhibition and Analysis
- COVID-19 Clinical Research Studies
- Acute Ischemic Stroke Management
- Eicosanoids and Hypertension Pharmacology
- Inflammatory mediators and NSAID effects
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
IGM Biosciences (United States)
2014-2024
New York Academy of Sciences
2023
John Wiley & Sons (Germany)
2023
Moss Landing Marine Laboratories
2023
Hudson Institute
2023
Genomic Health (United States)
2012
Trellis Bioscience (United States)
2008-2009
Millennium Engineering and Integration (United States)
2000-2001
University Medical Center
1999
Genentech
1996-1998
Retinal ischemia induces intraocular neovascularization, which often leads to glaucoma, vitreous hemorrhage, and retinal detachment, presumably by stimulating the release of angiogenic molecules. Vascular endothelial growth factor (VEGF) is an endothelial-cell-specific whose production increased hypoxia.
Vascular endothelial growth factor (VEGF) has been found to have various functions on cells, the most prominent of which is induction proliferation and differentiation. In this report we demonstrate that VEGF or a mutant, selectively binding Flk-1/KDR receptor, displayed high levels survival activity, whereas Flt-1-specific ligands failed promote serum-starved primary human cells. This activity was blocked by phosphatidylinositol 3′-kinase (PI3-kinase)-specific inhibitors wortmannin...
Vascular endothelial growth factor (VEGF) expression in various cell types is induced by hypoxia and other stimuli. VEGF mediates proliferation, angiogenesis, vascular growth, permeability via the receptors, kinase insert domain-containing receptor (KDR)/fetal liver 1 (Flk-1) FLT-1. Alanine-scanning mutagenesis was used to identify a positively charged surface that binding KDR/Flk-1. Arg82, Lys84 His86, located hairpin loop, were found be critical for KDR/Flk-1, while negatively residues,...
Vascular endothelial growth factor (VEGF)/vascular permeability (VPF), an cell (EC)-specific mitogen, stimulates angiogenesis in vivo, particularly ischemic regions. VEGF/VPF expression by cells of hypoxic tissues coincides with its two receptors, KDR and flt-1, ECs the same tissues. We investigated whether hypoxia or hypoxia-dependent conditions operate coordinating this phenomenon. Human umbilical vein microvascular were exposed to direct medium conditioned (CM) myoblasts maintained for 4...
Summary: Vascular endothelial growth factor (VEGF), a major regulator of angiogenesis, has therapeutic benefit in animal models coronary or limb ischemia. However, the hemodynamic effects VEGF have not been investigated. We examined on hemodynamics and cardiac performance. Mean arterial pressure (MAP), heart rate (HR), output, stroke volume, left ventricular (LV) dP/dt, hematocrit were measured before after intravenous injection conscious, instrumented rats. caused dose-dependent reduction...
We investigated the possibility that vascular endothelial growth factor (VEGF) treatment could regulate KDR/Flk-1 receptor expression in cells. Bovine adrenal cortex cells were incubated with 200 pmrhVEGF<sub>165</sub> for 0–7 days. Western blot analysis showed a 3–5-fold increase total KDR protein following 4-day VEGF treatment. Scatchard revealed induced 2–3-fold high affinity number (5.0 × 10<sup>4</sup>/cell<i>versus</i> 2.4 10<sup>4</sup>/cell) without significantly affecting binding...
Sixty-four variants of human tissue-type plasminogen activator (tPA) were produced using recombinant DNA techniques.Charged residues converted to alanine in clusters from one four changes per variant; these spanned all the domains molecule.The expressed by mammalian cells and analyzed for a variety properties.Variants tPA found that had reduced activity with respect each tested property; few cases increased was observed.Analysis effects prompted following conclusions: 1) charged nonprotease...
Background The thrombolytic properties of a new variant tissue plasminogen activator (TPA) (T103N, N117Q, KHRR 296-299 AAAA, or TNK-TPA) with longer plasma half-life, greater fibrin specificity, and increased resistance to inhibition by inhibitor (PAI-1) were investigated in rabbit thrombosed carotid artery model. Methods Results After 60 minutes arterial occlusion, TPA (1.5, 3.0, 6.0, 9.0 mg/kg as front-loaded IV infusion for 90 minutes; n=22) TNK-TPA (0.38, 0.75, 1.5 bolus; n=16) was...
Tissue plasminogen activator mediates excitotoxin-induced neurodegeneration and microglial activation in the mouse hippocampus. Here we show that tissue (tPA) acts a protease-independent manner to modulate of microglia, cells central nervous system with macrophage properties. Cultured microglia from tPA-deficient mice can phagocytose as efficiently wild-type microglia. However, mixed cortical cultures exhibit attenuated response lipopolysaccharide, judged by morphological changes, increased...
Native human Abs represent attractive drug candidates; however, the low frequency of B cells expressing high-quality has posed a barrier to discovery. Using novel single-cell phenotyping technology, we have overcome this discover targeting conserved but poorly immunogenic central motif respiratory syncytial virus (RSV) G protein. For entire cohort 24 subjects with recent RSV infection, producing meeting these stringent specificity criteria were rare, <10 per million. Several newly cloned...
Abstract Death receptor 5 (DR5) is an attractive target for cancer therapy due to its broad upregulated expression in multiple cancers and ability directly induce apoptosis. Though anti-DR5 IgG antibodies have been evaluated clinical trials, limited efficacy has attributed insufficient crosslinking. IGM-8444 engineered, multivalent agonistic IgM antibody with 10 binding sites DR5 that induces cell apoptosis through efficient multimerization. bound high avidity was substantially more potent...
ABSTRACT. PDGF-B is of central importance in mesangioproliferative diseases. PDGF-D, a new PDGF isoform, like PDGF-B, signals through the ββ-receptor. The present study first determined that PDGF-D mitogenic for rat mesangial cells and not inhibited by antagonist. Low levels mRNA were detected normal glomeruli. After induction nephritis rats anti–Thy 1.1 mAb, glomerular protein expression increased significantly from days 4 to 9 comparison with nonnephritic rats. Peak occurred 2 d later than...
Summary rt-PA-K, a variant of recombinant tissue-type plasminogen activator (rt-PA) with substitution amino acids 296 to 299 alanine (KHRR296-299AAAA) has increased fibrin-specificity and reduced sensitivity inhibitor-1; rt-PA-T, threonine 103 replaced by asparagine an additional glycosylation site clearance; rt-PA-N, 117 mutagen-ized glutamine lacks the high mannose carbohydrate side chain. We have investigated whether combination these properties in single molecule might yield improved...